KLOW 80mg Ireland | Buy KLOW 80mg | Research-Grade ≥99% Purity

KLOW 80mg is a precisely dosed, research-grade formulation combining Kojic Acid and Alpha-Arbutin — two of the most well-studied skin-brightening and melanin-inhibiting compounds in dermatology and pigmentation research — available to buy in Ireland with fast dispatch and full batch documentation included.

KLOW 80mg delivers a fixed-dose combination of Kojic Acid and Alpha-Arbutin in a single research-grade preparation, studied for their complementary and synergistic inhibition of tyrosinase — the key enzyme in melanin biosynthesis — across a wide range of pigmentation biology, dermatology, and skin science research applications. Researchers and institutions across Ireland can source verified, research-grade KLOW 80mg directly from our Irish supply, with domestic-speed dispatch and complete batch documentation.

✅ ≥99% Purity — HPLC & Mass Spectrometry Verified

✅ Batch-Specific Certificate of Analysis (CoA) Included

✅ Sterile Lyophilised Powder | GMP Manufactured

✅ Fast Dispatch to Ireland | Peptides Ireland Stock

What Is KLOW 80mg?

KLOW 80mg is a combined research formulation containing two pharmacologically distinct but mechanistically complementary tyrosinase-inhibiting compounds — Kojic Acid and Alpha-Arbutin — formulated together at a precise 80mg total dose for controlled laboratory and pre-clinical research use.

Kojic Acid is a naturally occurring fungal metabolite — first isolated from Aspergillus oryzae — that inhibits tyrosinase by chelating the copper ions in the enzyme’s active site. Copper is essential for tyrosinase catalytic function, and Kojic Acid’s copper-chelating activity directly disables the enzyme — preventing the conversion of tyrosine to DOPA and DOPA to dopaquinone, the early steps in the melanin synthesis pathway. Kojic Acid is one of the most widely studied and well-characterised tyrosinase inhibitors in dermatology research, with a well-established mechanism and a long history of use as a reference compound in pigmentation biology studies.

Alpha-Arbutin is a glycosylated hydroquinone derivative — a stabilised, lower-toxicity form of hydroquinone — that inhibits tyrosinase through a complementary mechanism involving competitive inhibition at the enzyme’s substrate binding site, as well as inhibition of melanosome maturation within melanocytes. Alpha-Arbutin is considered the most stable and research-relevant form of arbutin, with superior tyrosinase inhibitory potency and better stability compared to beta-arbutin, and without the direct cytotoxicity concerns associated with unmodified hydroquinone.

Together in KLOW 80mg, Kojic Acid and Alpha-Arbutin target tyrosinase through two distinct mechanisms — copper chelation and competitive substrate inhibition — providing a dual-mechanism research tool for studying combined tyrosinase inhibition, melanin pathway suppression, and hyperpigmentation biology with greater mechanistic depth than either compound alone.

What Does KLOW 80mg Do in Research?

In controlled laboratory and pre-clinical settings, KLOW 80mg is studied across a range of pigmentation biology, dermatology, and skin science research applications:

Tyrosinase Inhibition Research — The combined tyrosinase-inhibiting activity of Kojic Acid and Alpha-Arbutin is the central research focus of KLOW 80mg. Studies examine how the two compounds interact at the enzymatic level — whether their inhibitory effects are additive or synergistic, how dual-mechanism inhibition compares to single-compound tyrosinase suppression, and what the combined dose-response profile looks like in cell-free and cell-based tyrosinase activity assays.

Melanin Synthesis and Pigmentation Research — KLOW 80mg is used to study the suppression of melanin biosynthesis in melanocyte cell culture models — examining how combined tyrosinase inhibition affects melanin production, melanosome formation, and the broader pigmentation biology of melanocytes under stimulated and unstimulated conditions.

Hyperpigmentation Biology Research — Research has used KLOW-type formulations to study the biology of hyperpigmentation — including UV-induced pigmentation, post-inflammatory hyperpigmentation, and constitutive melanin overproduction models — examining how dual tyrosinase inhibition affects pigment accumulation in cell and tissue models relevant to hyperpigmentation pathology research.

Synergy and Combination Research — A key research application of KLOW 80mg is studying the pharmacological interaction between Kojic Acid and Alpha-Arbutin — examining whether their distinct inhibitory mechanisms produce synergistic tyrosinase suppression greater than the sum of their individual effects, and what the optimal ratio and combined dose looks like for maximal inhibitory activity in research models.

Melanocyte Biology Research — Beyond tyrosinase inhibition, KLOW 80mg is studied in the context of broader melanocyte biology — examining effects on melanocyte viability, morphology, signalling pathway activity, and gene expression related to melanogenesis, including MITF (microphthalmia-associated transcription factor) and downstream melanogenic enzyme expression.

Antioxidant Research — Both Kojic Acid and Alpha-Arbutin have antioxidant properties in addition to their tyrosinase-inhibitory activity, and KLOW 80mg is studied for combined antioxidant effects in cell oxidative stress models — contributing to research on the intersection between oxidative stress, melanogenesis, and skin biology.

Dermatology Formulation Research — KLOW 80mg is used as a reference compound preparation in dermatology research examining skin-brightening formulation biology — studying bioavailability, penetration, stability, and activity of combined Kojic Acid and Alpha-Arbutin in skin model systems and tissue penetration studies.

UV-Induced Melanogenesis Research — Studies have used KLOW-type formulations in UV-stimulated melanocyte and skin models to examine how combined tyrosinase inhibition suppresses UV-induced upregulation of melanogenesis — contributing to research on photoprotection biology and the cellular response to UV-driven pigmentation signalling.

What Do Studies Say About KLOW / Kojic Acid and Alpha-Arbutin?

The individual components of KLOW 80mg have extensive, well-established research profiles, and combination studies are an active and growing area:

Kojic Acid — Well-Established Tyrosinase Inhibitor — Kojic Acid is one of the most extensively characterised tyrosinase inhibitors in the dermatology and pigmentation research literature. Studies have consistently demonstrated potent inhibition of both mushroom and human tyrosinase through copper chelation, with well-documented effects on melanin production in melanocyte cell culture models and pre-clinical skin models. It is widely used as a positive control reference compound in tyrosinase inhibition research.

Alpha-Arbutin — Superior Stability and Potency vs Beta-Arbutin — Research has confirmed that Alpha-Arbutin has greater tyrosinase inhibitory potency than its beta-arbutin isomer, with better aqueous stability and a more favourable safety profile than unmodified hydroquinone in cell-based models. Studies have characterised its competitive inhibition mechanism at the tyrosinase substrate binding site and its additional effects on melanosome maturation.

Complementary Mechanisms Confirmed — Research has confirmed that Kojic Acid and Alpha-Arbutin inhibit tyrosinase through distinct and non-overlapping mechanisms — copper chelation versus substrate site competition — providing the mechanistic rationale for combination use and the hypothesis that combined application produces superior tyrosinase suppression compared to either compound alone.

Synergistic Activity in Combination Studies — Studies examining Kojic Acid and Alpha-Arbutin in combination have reported evidence of additive to synergistic tyrosinase inhibition — with combined preparations producing greater melanin suppression in cell models than equivalent concentrations of either compound individually, supporting the rationale for fixed-combination research preparations like KLOW 80mg.

Effects on MITF and Melanogenic Gene Expression — Research has examined how tyrosinase inhibition by Kojic Acid and arbutin-type compounds affects upstream melanogenic signalling — including MITF expression and the transcriptional regulation of tyrosinase and related enzymes (TRP-1, TRP-2/DCT) — contributing to a fuller mechanistic picture of how these compounds interact with the melanogenesis pathway beyond direct enzymatic inhibition.

Antioxidant Properties Documented — Both components have demonstrated antioxidant activity in cell models, with research documenting free radical scavenging and reduction of oxidative stress markers — properties that are relevant to the broader skin biology context in which tyrosinase inhibition research is conducted.

How Does KLOW 80mg Compare to Other Pigmentation Research Compounds?

Feature	KLOW 80mg	Kojic Acid Alone	Alpha-Arbutin Alone	Hydroquinone
Composition	Kojic Acid + Alpha-Arbutin combined	Single compound	Single compound	Single compound
Tyrosinase Inhibition Mechanism	Dual — copper chelation + substrate competition	Copper chelation only	Substrate site competition only	Substrate competition / enzyme inhibition
Research Advantage	Dual-mechanism / synergy studies	Reference inhibitor	Stable arbutin research	Reference but cytotoxicity concerns
Melanocyte Safety Profile	Favourable in research models	Generally well tolerated	Favourable vs hydroquinone	Cytotoxicity at higher concentrations
Best For	Combination / synergy / pigmentation biology	Mechanistic tyrosinase research	Arbutin biology / stable brightening research	Reference compound / comparative studies

KLOW 80mg is the only fixed-combination preparation providing dual-mechanism tyrosinase inhibition in a single pre-dosed research formulation — making it the most efficient tool for studying combined Kojic Acid and Alpha-Arbutin biology without the need to prepare individual compound solutions and combine them manually.

Product Specifications

Parameter	Detail
Name	KLOW 80mg
Composition	Kojic Acid + Alpha-Arbutin
Total Dose	80mg per vial
Mechanism	Dual tyrosinase inhibition — copper chelation (Kojic Acid) + substrate competition (Alpha-Arbutin)
Primary Research Area	Pigmentation biology / melanogenesis / dermatology
Purity	≥99% HPLC & MS Verified
Form	Sterile Lyophilised Powder
Solubility	Sterile water, bacteriostatic water, PBS
Storage (Powder)	-20°C, protect from light
Storage (Reconstituted)	2–8°C, use promptly
Manufacturing	GMP Manufactured

Buy KLOW 80mg in Ireland — What’s Included

Every order of KLOW 80mg in Ireland includes:

✅ Batch-Specific Certificate of Analysis (CoA)

✅ HPLC Chromatogram

✅ Mass Spectrometry Confirmation

✅ Sterility & Endotoxin Testing Report

✅ Reconstitution Protocol

✅ Technical Research Support

Frequently Asked Questions

Can I buy KLOW 80mg in Ireland? Yes — we supply research-grade KLOW 80mg to researchers and institutions across Ireland with fast dispatch and full batch documentation. This compound is supplied strictly for laboratory research purposes only.

What is KLOW 80mg and what does it contain? KLOW 80mg is a fixed-dose combination research formulation containing Kojic Acid and Alpha-Arbutin — two complementary tyrosinase-inhibiting compounds — formulated together at a total dose of 80mg per vial for pre-clinical and laboratory research use. The combination provides dual-mechanism tyrosinase inhibition through Kojic Acid’s copper-chelating activity and Alpha-Arbutin’s competitive substrate site inhibition.

Why combine Kojic Acid and Alpha-Arbutin in one formulation? Kojic Acid and Alpha-Arbutin inhibit tyrosinase through completely different mechanisms — one by disabling the enzyme’s copper-dependent active site, the other by competing at the substrate binding site. Combining them in a single preparation allows researchers to study dual-mechanism inhibition, assess potential synergistic effects, and model combined tyrosinase suppression more efficiently than using individual compounds separately.

What is tyrosinase and why is it important in pigmentation research? Tyrosinase is the rate-limiting enzyme in melanin biosynthesis — the biological pathway responsible for producing the pigment melanin in melanocytes. It catalyses the conversion of tyrosine to DOPA and then to dopaquinone, the first committed steps in melanin production. Inhibiting tyrosinase is the primary pharmacological strategy for suppressing melanogenesis in pigmentation biology research, making it the central target for compounds like Kojic Acid and Alpha-Arbutin.

How does Alpha-Arbutin differ from regular (beta) arbutin? Alpha-Arbutin is the alpha-glycoside isomer of arbutin, while standard arbutin is the beta-glycoside form. Research has confirmed that Alpha-Arbutin has significantly greater tyrosinase inhibitory potency than beta-arbutin at equivalent concentrations, along with better aqueous stability — making it the preferred form for rigorous pigmentation research where compound potency and consistency are important.

What purity is recommended for KLOW 80mg research? ≥99% purity is strongly recommended for tyrosinase activity assays, melanin quantification studies, melanocyte cell culture models, and any research where compound quality directly affects inhibitory activity measurements and reproducibility. All KLOW 80mg Ireland stock is independently verified to ≥99%.

How do I reconstitute KLOW 80mg for laboratory use? Allow the vial to reach room temperature before opening. Reconstitute in sterile water or bacteriostatic water by adding solvent slowly down the inside wall of the vial and swirling gently — do not shake. Both Kojic Acid and Alpha-Arbutin are water-soluble and should dissolve readily. Use promptly after reconstitution, or aliquot and store at -80°C to preserve compound stability and activity across multiple experimental uses. Protect from light during storage and handling as both components can be light-sensitive.

Research Disclaimer

KLOW 80mg is supplied exclusively for legitimate scientific research purposes conducted within licensed laboratory environments. This product is not intended for human consumption, self-administration, or any therapeutic application. It must be handled by qualified researchers in compliance with applicable Irish and EU regulations and institutional ethics guidelines. By purchasing, you confirm that this compound will be used solely for approved in-vitro or pre-clinical research purposes.